{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:14:16Z","timestamp":1791216856445,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"47","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,11,24]]},"DOI":"10.1038\/onc.2016.86","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T07:07:18Z","timestamp":1459753638000},"page":"6045-6052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting CK2-driven non-oncogene addiction in B-cell tumors"],"prefix":"10.1038","volume":"35","author":[{"given":"E","family":"Mandato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Manni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Zaffino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"key":"BFonc201686_CR1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cell.2007.09.007","volume":"130","author":"NL Solimini","year":"2007","unstructured":"Solimini NL, Luo J, Elledge SJ . Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007; 130: 986\u2013988.","journal-title":"Cell"},{"key":"BFonc201686_CR2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo J, Solimini NL, Elledge SJ . Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823\u2013837.","journal-title":"Cell"},{"key":"BFonc201686_CR3","first-page":"535","volume":"6","author":"J Jonkers","year":"2004","unstructured":"Jonkers J, Berns A . Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004; 6: 535\u2013538.","journal-title":"Cancer Cell"},{"key":"BFonc201686_CR4","first-page":"1","volume":"1","author":"L Galluzzi","year":"2011","unstructured":"Galluzzi L, Vitale I, Kroemer G . Past, present, and future of molecular and cellular oncology. Front Oncol 2011; 1: 1.","journal-title":"Front Oncol"},{"key":"BFonc201686_CR5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nrclinonc.2012.123","volume":"9","author":"KN Maxwell","year":"2012","unstructured":"Maxwell KN, Domchek SM . Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012; 9: 520\u2013528.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFonc201686_CR6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947\u2013959.","journal-title":"Blood"},{"key":"BFonc201686_CR7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.2012.064923","volume":"97","author":"LI Aronson","year":"2012","unstructured":"Aronson LI, Davies FE . DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 2012; 97: 1119\u20131130.","journal-title":"Haematologica"},{"key":"BFonc201686_CR8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.275.5299.540","volume":"275","author":"HW Mittrucker","year":"1997","unstructured":"Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A et al. Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540\u2013543.","journal-title":"Science"},{"key":"BFonc201686_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.it.2008.07.006","volume":"29","author":"R Lu","year":"2008","unstructured":"Lu R . Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008; 29: 487\u2013492.","journal-title":"Trends Immunol"},{"key":"BFonc201686_CR10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226\u2013231.","journal-title":"Nature"},{"key":"BFonc201686_CR11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL III, Emre NC, Ceribelli M, Zhang M, Wright G et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723\u2013737.","journal-title":"Cancer Cell"},{"key":"BFonc201686_CR12","doi-asserted-by":"crossref","first-page":"189ra178","DOI":"10.1126\/scitranslmed.3005814","volume":"5","author":"A Riabinska","year":"2013","unstructured":"Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med 2013; 5: 189ra178.","journal-title":"Sci Transl Med"},{"key":"BFonc201686_CR13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V94.2.748","volume":"94","author":"C Schaffner","year":"1999","unstructured":"Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P . Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748\u2013753.","journal-title":"Blood"},{"key":"BFonc201686_CR14","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.050400997","volume":"97","author":"C Schaffner","year":"2000","unstructured":"Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P . Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97: 2773\u20132778.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201686_CR15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1365-2141.2008.07281.x","volume":"142","author":"B Austen","year":"2008","unstructured":"Austen B, Barone G, Reiman A, Byrd PJ, Baker C, Starczynski J et al. Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients. Br J Haematol 2008; 142: 925\u2013933.","journal-title":"Br J Haematol"},{"key":"BFonc201686_CR16","first-page":"280","volume":"18","author":"A Sawas","year":"2011","unstructured":"Sawas A, Diefenbach C, O'Connor OA . New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol 2011; 18: 280\u2013287.","journal-title":"Curr Opin Hematol"},{"key":"BFonc201686_CR17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/08830185.2013.818141","volume":"32","author":"RJ Hill","year":"2013","unstructured":"Hill RJ, Lou Y, Tan SL . B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities. Int Rev Immunol 2013; 32: 377\u2013396.","journal-title":"Int Rev Immunol"},{"key":"BFonc201686_CR18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/asheducation-2013.1.553","volume":"2013","author":"N Fowler","year":"2013","unstructured":"Fowler N, Davis E . Targeting B-cell receptor signaling: changing the paradigm. Hematol Am Soc Hematol Educ Program 2013; 2013: 553\u2013560.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"BFonc201686_CR19","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-14-1462","volume":"21","author":"I Kuiatse","year":"2015","unstructured":"Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM et al. Targeting the spleen tyrosine kinase with fostamatinib as a strategy against waldenstrom macroglobulinemia. Clin Cancer Res 2015; 21: 2538\u20132545.","journal-title":"Clin Cancer Res"},{"key":"BFonc201686_CR20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2013.37","volume":"27","author":"SE Herman","year":"2013","unstructured":"Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW . Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013; 27: 1769\u20131773.","journal-title":"Leukemia"},{"key":"BFonc201686_CR21","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406\u20133413.","journal-title":"Blood"},{"key":"BFonc201686_CR22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PPO.0000000000000170","volume":"22","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Treon SP, Davids MS . Inhibition of the bruton tyrosine kinase pathway in B-cell lymphoproliferative disorders. Cancer J 2016; 22: 34\u201339.","journal-title":"Cancer J"},{"key":"BFonc201686_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM . B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 2015; 52: 77\u201385.","journal-title":"Semin Hematol"},{"key":"BFonc201686_CR24","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","volume":"29","author":"K Balakrishnan","year":"2015","unstructured":"Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL. Leukemia 2015; 29: 1811\u20131822.","journal-title":"Leukemia"},{"key":"BFonc201686_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CCO.0000000000000113","volume":"26","author":"E Curran","year":"2014","unstructured":"Curran E, Smith SM . Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol 2014; 26: 469\u2013475.","journal-title":"Curr Opin Oncol"},{"key":"BFonc201686_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021469","volume":"369","author":"DW Litchfield","year":"2003","unstructured":"Litchfield DW . Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369: 1\u201315.","journal-title":"Biochem J"},{"key":"BFonc201686_CR27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00018-009-9150-2","volume":"66","author":"NA St-Denis","year":"2009","unstructured":"St-Denis NA, Litchfield DW . Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 2009; 66: 1817\u20131829.","journal-title":"Cell Mol Life Sci"},{"key":"BFonc201686_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/biof.96","volume":"36","author":"JH Trembley","year":"2010","unstructured":"Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C et al. Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 2010; 36: 187\u2013195.","journal-title":"Biofactors"},{"key":"BFonc201686_CR29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","volume":"12","author":"G Di Maira","year":"2005","unstructured":"Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. Protein kinase CK2 phosphorylates and upregulates Akt\/PKB. Cell Death Differ 2005; 12: 668\u2013677.","journal-title":"Cell Death Differ"},{"key":"BFonc201686_CR30","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00018-009-0108-1","volume":"66","author":"G Di Maira","year":"2009","unstructured":"Di Maira G, Brustolon F, Pinna LA, Ruzzene M . Dephosphorylation and inactivation of Akt\/PKB is counteracted by protein kinase CK2 in HEK 293\u2009T cells. Cell Mol Life Sci 2009; 66: 3363\u20133373.","journal-title":"Cell Mol Life Sci"},{"key":"BFonc201686_CR31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.cub.2006.09.034","volume":"16","author":"S Wang","year":"2006","unstructured":"Wang S, Jones KA . CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol 2006; 16: 2239\u20132244.","journal-title":"Curr Biol"},{"key":"BFonc201686_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11010-011-0959-2","volume":"356","author":"M Ruzzene","year":"2011","unstructured":"Ruzzene M, Tosoni K, Zanin S, Cesaro L, Pinna LA . Protein kinase CK2 accumulation in \u2018oncophilic\u2019 cells: causes and effects. Mol Cell Biochem 2011; 356: 5\u201310.","journal-title":"Mol Cell Biochem"},{"key":"BFonc201686_CR33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0962-8924(02)02279-1","volume":"12","author":"K Ahmed","year":"2002","unstructured":"Ahmed K, Gerber DA, Cochet C . Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 2002; 12: 226\u2013230.","journal-title":"Trends Cell Biol"},{"key":"BFonc201686_CR34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbapap.2009.07.018","volume":"1804","author":"M Ruzzene","year":"2010","unstructured":"Ruzzene M, Pinna LA . Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010; 1804: 499\u2013504.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc201686_CR35","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00018-009-9154-y","volume":"66","author":"JH Trembley","year":"2009","unstructured":"Trembley JH, Wang G, Unger G, Slaton J, Ahmed K . Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858\u20131867.","journal-title":"Cell Mol Life Sci"},{"key":"BFonc201686_CR36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.385","volume":"26","author":"F Piazza","year":"2012","unstructured":"Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G . Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012; 26: 1174\u20131179.","journal-title":"Leukemia"},{"key":"BFonc201686_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646\u2013674.","journal-title":"Cell"},{"key":"BFonc201686_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C . PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140\u2013156.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc201686_CR39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","volume":"7","author":"S Schubbert","year":"2007","unstructured":"Schubbert S, Shannon K, Bollag G . Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295\u2013308.","journal-title":"Nat Rev Cancer"},{"key":"BFonc201686_CR40","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1074\/jbc.M009134200","volume":"276","author":"J Torres","year":"2001","unstructured":"Torres J, Pulido R . The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001; 276: 993\u2013998.","journal-title":"J Biol Chem"},{"key":"BFonc201686_CR41","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1128\/MCB.20.14.5010-5018.2000","volume":"20","author":"F Vazquez","year":"2000","unstructured":"Vazquez F, Ramaswamy S, Nakamura N, Sellers WR . Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000; 20: 5010\u20135018.","journal-title":"Mol Cell Biol"},{"key":"BFonc201686_CR42","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1128\/MCB.05424-11","volume":"31","author":"A Plotnikov","year":"2011","unstructured":"Plotnikov A, Chuderland D, Karamansha Y, Livnah O, Seger R . Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol Cell Biol 2011; 31: 3515\u20133530.","journal-title":"Mol Cell Biol"},{"key":"BFonc201686_CR43","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1091\/mbc.E14-10-1453","volume":"26","author":"G Schevzov","year":"2015","unstructured":"Schevzov G, Kee AJ, Wang B, Sequeira VB, Hook J, Coombes JD et al. Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments. Mol Biol Cell 2015; 26: 2475\u20132490.","journal-title":"Mol Biol Cell"},{"key":"BFonc201686_CR44","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-04-0576","volume":"10","author":"K Izeradjene","year":"2004","unstructured":"Izeradjene K, Douglas L, Delaney A, Houghton JA . Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 2004; 10: 6650\u20136660.","journal-title":"Clin Cancer Res"},{"key":"BFonc201686_CR45","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/sj.onc.1208397","volume":"24","author":"K Izeradjene","year":"2005","unstructured":"Izeradjene K, Douglas L, Delaney A, Houghton JA . Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 2005; 24: 2050\u20132058.","journal-title":"Oncogene"},{"key":"BFonc201686_CR46","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1038\/sj.emboj.7600827","volume":"24","author":"S Shin","year":"2005","unstructured":"Shin S, Lee Y, Kim W, Ko H, Choi H, Kim K . Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J 2005; 24: 3532\u20133542.","journal-title":"EMBO J"},{"key":"BFonc201686_CR47","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1158\/0008-5472.CAN-05-2772","volume":"66","author":"G Wang","year":"2006","unstructured":"Wang G, Ahmad KA, Ahmed K . Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 2006; 66: 2242\u20132249.","journal-title":"Cancer Res"},{"key":"BFonc201686_CR48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbapap.2009.11.001","volume":"1804","author":"JS Duncan","year":"2010","unstructured":"Duncan JS, Turowec JP, Vilk G, Li SS, Gloor GB, Litchfield DW . Regulation of cell proliferation and survival: convergence of protein kinases and caspases. Biochim Biophys Acta 2010; 1804: 505\u2013510.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc201686_CR49","doi-asserted-by":"crossref","first-page":"ra30","DOI":"10.1126\/scisignal.2001682","volume":"4","author":"JS Duncan","year":"2011","unstructured":"Duncan JS, Turowec JP, Duncan KE, Vilk G, Wu C, Luscher B et al. A peptide-based target screen implicates the protein kinase CK2 in the global regulation of caspase signaling. Sci Signal 2011; 4: ra30.","journal-title":"Sci Signal"},{"key":"BFonc201686_CR50","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1042\/bj20030662","volume":"378","author":"S Pospisilova","year":"2004","unstructured":"Pospisilova S, Brazda V, Kucharikova K, Luciani MG, Hupp TR, Skladal P et al. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem J 2004; 378: 939\u2013947.","journal-title":"Biochem J"},{"key":"BFonc201686_CR51","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cellsig.2009.11.014","volume":"22","author":"ML Cox","year":"2010","unstructured":"Cox ML, Meek DW . Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell Signal 2010; 22: 564\u2013571.","journal-title":"Cell Signal"},{"key":"BFonc201686_CR52","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/sj.onc.1201854","volume":"16","author":"E Landesman-Bollag","year":"1998","unstructured":"Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC . p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 1998; 16: 2965\u20132974.","journal-title":"Oncogene"},{"key":"BFonc201686_CR53","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejca.2010.11.028","volume":"47","author":"S Giusiano","year":"2011","unstructured":"Giusiano S, Cochet C, Filhol O, Duchemin-Pelletier E, Secq V, Bonnier P et al. Protein kinase CK2alpha subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays. Eur J Cancer 2011; 47: 792\u2013801.","journal-title":"Eur J Cancer"},{"key":"BFonc201686_CR54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0167-4889(00)00100-2","volume":"1498","author":"M Kriajevska","year":"2000","unstructured":"Kriajevska M, Bronstein IB, Scott DJ, Tarabykina S, Fischer-Larsen M, Issinger O et al. Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of nonmuscle myosin. Biochim Biophys Acta 2000; 1498: 252\u2013263.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc201686_CR55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2011.10.046","volume":"415","author":"D Drygin","year":"2011","unstructured":"Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R et al. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun 2011; 415: 163\u2013167.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc201686_CR56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.17219\/acem\/37040","volume":"23","author":"M Montenarh","year":"2014","unstructured":"Montenarh M . Protein kinase CK2 and angiogenesis. Adv Clin Exp Med 2014; 23: 153\u2013158.","journal-title":"Adv Clin Exp Med"},{"key":"BFonc201686_CR57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ijc.21268","volume":"117","author":"D Mottet","year":"2005","unstructured":"Mottet D, Ruys SP, Demazy C, Raes M, Michiels C . Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 2005; 117: 764\u2013774.","journal-title":"Int J Cancer"},{"key":"BFonc201686_CR58","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","volume":"70","author":"A Siddiqui-Jain","year":"2010","unstructured":"Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288\u201310298.","journal-title":"Cancer Res"},{"key":"BFonc201686_CR59","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/onc.2012.165","volume":"32","author":"A Deshiere","year":"2013","unstructured":"Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Combes F, Vandenbrouck Y et al. Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction. Oncogene 2013; 32: 1373\u20131383.","journal-title":"Oncogene"},{"key":"BFonc201686_CR60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11010-011-0942-y","volume":"356","author":"A Deshiere","year":"2011","unstructured":"Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Forcet C, Cochet C et al. Regulation of epithelial to mesenchymal transition: CK2beta on stage. Mol Cell Biochem 2011; 356: 11\u201320.","journal-title":"Mol Cell Biochem"},{"key":"BFonc201686_CR61","doi-asserted-by":"crossref","first-page":"50206","DOI":"10.1074\/jbc.M209820200","volume":"277","author":"DM Keller","year":"2002","unstructured":"Keller DM, Lu H . P53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex. J Biol Chem 2002; 277: 50206\u201350213.","journal-title":"J Biol Chem"},{"key":"BFonc201686_CR62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1097-2765(01)00176-9","volume":"7","author":"DM Keller","year":"2001","unstructured":"Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 2001; 7: 283\u2013292.","journal-title":"Mol Cell"},{"key":"BFonc201686_CR63","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1038\/onc.2010.337","volume":"29","author":"BB Olsen","year":"2010","unstructured":"Olsen BB, Issinger OG, Guerra B . Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells. Oncogene 2010; 29: 6016\u20136026.","journal-title":"Oncogene"},{"key":"BFonc201686_CR64","first-page":"7","volume":"13","author":"BB Olsen","year":"2012","unstructured":"Olsen BB, Wang SY, Svenstrup TH, Chen BP, Guerra B . Protein kinase CK2 localizes to sites of DNA double-strand break regulating the cellular response to DNA damage. BMC. Mol Biol 2012; 13: 7.","journal-title":"Mol Biol"},{"key":"BFonc201686_CR65","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.dnarep.2011.07.004","volume":"10","author":"CE Strom","year":"2011","unstructured":"Strom CE, Mortusewicz O, Finch D, Parsons JL, Lagerqvist A, Johansson F et al. CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair (Amst) 2011; 10: 961\u2013969.","journal-title":"DNA Repair (Amst)"},{"key":"BFonc201686_CR66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2013.11.008","volume":"345","author":"B Guerra","year":"2014","unstructured":"Guerra B, Iwabuchi K, Issinger OG . Protein kinase CK2 is required for the recruitment of 53BP1 to sites of DNA double-strand break induced by radiomimetic drugs. Cancer Lett 2014; 345: 115\u2013123.","journal-title":"Cancer Lett"},{"key":"BFonc201686_CR67","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1093\/nar\/gkv528","volume":"43","author":"B Peng","year":"2015","unstructured":"Peng B, Wang J, Hu Y, Zhao H, Hou W, Zhao H et al. Modulation of LSD1 phosphorylation by CK2\/WIP1 regulates RNF168-dependent 53BP1 recruitment in response to DNA damage. Nucleic Acids Res 2015; 43: 5936\u20135947.","journal-title":"Nucleic Acids Res"},{"key":"BFonc201686_CR68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200708210","volume":"181","author":"F Melander","year":"2008","unstructured":"Melander F, Bekker-Jensen S, Falck J, Bartek J, Mailand N, Lukas J . Phosphorylation of SDT repeats in the MDC1 N terminus triggers retention of NBS1 at the DNA damage-modified chromatin. J Cell Biol 2008; 181: 213\u2013226.","journal-title":"J Cell Biol"},{"key":"BFonc201686_CR69","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2012.01.021","volume":"45","author":"SV Khoronenkova","year":"2012","unstructured":"Khoronenkova SV, Dianova II, Ternette N, Kessler BM, Parsons JL, Dianov GL . ATM-dependent downregulation of USP7\/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell 2012; 45: 801\u2013813.","journal-title":"Mol Cell"},{"key":"BFonc201686_CR70","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1038\/ncomms8227","volume":"6","author":"M Kalathur","year":"2015","unstructured":"Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I et al. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun 2015; 6: 7227.","journal-title":"Nat Commun"},{"key":"BFonc201686_CR71","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1038\/cddis.2012.10","volume":"3","author":"D Dixit","year":"2012","unstructured":"Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E . Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 2012; 3: e271.","journal-title":"Cell Death Dis"},{"key":"BFonc201686_CR72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s10495-009-0316-z","volume":"14","author":"MC Caino","year":"2009","unstructured":"Caino MC, Meshki J, Kazanietz MG . Hallmarks for senescence in carcinogenesis: novel signaling players. Apoptosis 2009; 14: 392\u2013408.","journal-title":"Apoptosis"},{"key":"BFonc201686_CR73","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1128\/MCB.24.9.4065-4074.2004","volume":"24","author":"Y Miyata","year":"2004","unstructured":"Miyata Y, Nishida E . CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol 2004; 24: 4065\u20134074.","journal-title":"Mol Cell Biol"},{"key":"BFonc201686_CR74","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1007\/s00018-009-9152-0","volume":"66","author":"Y Miyata","year":"2009","unstructured":"Miyata Y . Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci 2009; 66: 1840\u20131849.","journal-title":"Cell Mol Life Sci"},{"key":"BFonc201686_CR75","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.1038\/sj.onc.1207156","volume":"22","author":"S Mishra","year":"2003","unstructured":"Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N et al. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr\/Abl and mediates proliferation of Bcr\/Abl-expressing cells. Oncogene 2003; 22: 8255\u20138262.","journal-title":"Oncogene"},{"key":"BFonc201686_CR76","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.leu.2404460","volume":"21","author":"S Mishra","year":"2007","unstructured":"Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J et al. Treatment of P190 Bcr\/Abl lymphoblastic leukemia cells with inhibitors of the serine\/threonine kinase CK2. Leukemia 2007; 21: 178\u2013180.","journal-title":"Leukemia"},{"key":"BFonc201686_CR77","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3324\/haematol.2013.096438","volume":"99","author":"AM Gomes","year":"2014","unstructured":"Gomes AM, Soares MVD, Ribeiro P, Caldas J, P\u00f3voa V, Martins LR et al. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K\/Akt pathway despite high PTEN protein levels. Haematologica 2014; 99: 1062\u20131068.","journal-title":"Haematologica"},{"key":"BFonc201686_CR78","first-page":"1","volume":"3","author":"P Kastner","year":"2013","unstructured":"Kastner P, Dupuis A, Gaub MP, Herbrecht R, Lutz P, Chan S . Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res 2013; 3: 1\u201313.","journal-title":"Am J Blood Res"},{"key":"BFonc201686_CR79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11010-011-0964-5","volume":"356","author":"S Dovat","year":"2011","unstructured":"Dovat S, Song C, Payne KJ, Li Z . Ikaros, CK2 kinase, and the road to leukemia. Mol Cell Biochem 2011; 356: 201\u2013207.","journal-title":"Mol Cell Biochem"},{"key":"BFonc201686_CR80","doi-asserted-by":"crossref","first-page":"13869","DOI":"10.1074\/jbc.M900209200","volume":"284","author":"M Popescu","year":"2009","unstructured":"Popescu M, Gurel Z, Ronni T, Song C, Hung KY, Payne KJ et al. Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1. J Biol Chem 2009; 284: 13869\u201313880.","journal-title":"J Biol Chem"},{"key":"BFonc201686_CR81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4331\/wjbc.v2.i6.126","volume":"2","author":"C Song","year":"2011","unstructured":"Song C, Li Z, Erbe AK, Savic A, Dovat S . Regulation of Ikaros function by casein kinase 2 and protein phosphatase 1. World J Biol Chem 2011; 2: 126\u2013131.","journal-title":"World J Biol Chem"},{"key":"BFonc201686_CR82","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2015-06-651505","volume":"126","author":"C Song","year":"2015","unstructured":"Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH et al. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood 2015; 126: 1813\u20131822.","journal-title":"Blood"},{"key":"BFonc201686_CR83","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.18632\/oncotarget.6361","volume":"7","author":"F Buontempo","year":"2015","unstructured":"Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP\/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget 2015; 7: 1323\u20131340.","journal-title":"Oncotarget"},{"key":"BFonc201686_CR84","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2009-10-248054","volume":"116","author":"M Shehata","year":"2010","unstructured":"Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K\/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010; 116: 2513\u20132521.","journal-title":"Blood"},{"key":"BFonc201686_CR85","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2010-04-277947","volume":"116","author":"LR Martins","year":"2010","unstructured":"Martins LR, Lucio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724\u20132731.","journal-title":"Blood"},{"key":"BFonc201686_CR86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/leu.2013.232","volume":"28","author":"LR Martins","year":"2014","unstructured":"Martins LR, Lucio P, Melao A, Antunes I, Cardoso BA, Stansfield R et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 2014; 28: 179\u2013182.","journal-title":"Leukemia"},{"key":"BFonc201686_CR87","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2013.228","volume":"27","author":"RC Prins","year":"2013","unstructured":"Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE . CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia 2013; 27: 2094\u20132096.","journal-title":"Leukemia"},{"key":"BFonc201686_CR88","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2005-11-013672","volume":"108","author":"FA Piazza","year":"2006","unstructured":"Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698\u20131707.","journal-title":"Blood"},{"key":"BFonc201686_CR89","doi-asserted-by":"crossref","first-page":"e75280","DOI":"10.1371\/journal.pone.0075280","volume":"8","author":"S Manni","year":"2013","unstructured":"Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M et al. Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One 2013; 8: e75280.","journal-title":"PLoS One"},{"key":"BFonc201686_CR90","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-266320","volume":"118","author":"Y Zheng","year":"2011","unstructured":"Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 2011; 118: 156\u2013166.","journal-title":"Blood"},{"key":"BFonc201686_CR91","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.18632\/oncotarget.1852","volume":"5","author":"S Aparicio-Siegmund","year":"2014","unstructured":"Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstadt D et al. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1\/3 and constitutive STAT3 activation. Oncotarget 2014; 5: 2131\u20132148.","journal-title":"Oncotarget"},{"key":"BFonc201686_CR92","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-11-1789","volume":"18","author":"S Manni","year":"2012","unstructured":"Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A et al. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res 2012; 18: 1888\u20131900.","journal-title":"Clin Cancer Res"},{"key":"BFonc201686_CR93","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2014.178","volume":"28","author":"S Manni","year":"2014","unstructured":"Manni S, Toscani D, Mandato E, Brancalion A, Quotti Tubi L, Macaccaro P et al. Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia 2014; 28: 2094\u20132097.","journal-title":"Leukemia"},{"key":"BFonc201686_CR94","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.18632\/oncotarget.3446","volume":"6","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Piazza F, Agostinelli C, Fuligni F, Benvenuti P, Mandato E et al. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget 2015; 6: 6544\u20136552.","journal-title":"Oncotarget"},{"key":"BFonc201686_CR95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2012.12.006","volume":"49","author":"SY Wu","year":"2013","unstructured":"Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM . Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 2013; 49: 843\u2013857.","journal-title":"Mol Cell"},{"key":"BFonc201686_CR96","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","volume":"5","author":"F Cottini","year":"2015","unstructured":"Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG et al. Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer Discov 2015; 5: 972\u2013987.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc201686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201686","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:42:42Z","timestamp":1647880962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc201686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":96,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2016,11,24]]}},"alternative-id":["BFonc201686"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.86","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]},"assertion":[{"value":"6 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}